Skip to main
ANTX
ANTX logo

ANTX Stock Forecast & Price Target

ANTX Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

AN2 Therapeutics Inc. is advancing its boron-based therapeutic pipeline, particularly with epetraborole, which has shown favorable safety and tolerability in Phase 2 trials for non-tuberculous mycobacterial (NTM) infections. The observed clinically meaningful improvements in quality of life for patients, alongside strong pre-clinical data suggesting efficacy for treating more challenging forms of NTM, bolster the company's position in the biopharmaceutical market. Overall, the potential of epetraborole to become a key therapeutic option, especially for refractory patients, indicates a positive outlook for AN2 Therapeutics's future financial performance and market presence.

Bears say

AN2 Therapeutics Inc. faces significant challenges as it grapples with disappointing clinical trial results that underscore the potential efficacy limitations of its drug candidates, particularly epetraborole. The company has a history of financial losses and lacks a proven track record of profitability, raising concerns about its viability without successful commercialization of its pipeline products. Additionally, there are substantial risks related to litigation, regulatory approvals, and competition, which could impede AN2's ability to develop and bring its drugs to market effectively.

ANTX has been analyzed by 6 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AN2 Therapeutics Inc (ANTX) Forecast

Analysts have given ANTX a Buy based on their latest research and market trends.

According to 6 analysts, ANTX has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AN2 Therapeutics Inc (ANTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.